Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALIREZA FARABI

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1598889008
CMS profile
72414
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$51,162.91

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALIREZA FARABI

NPI 1598889008 · CMS profile ID 72414

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598889008?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALIREZA FARABI, NPI 1598889008, CMS profile ID 72414. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598889008?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ALIREZA FARABI, NPI 1598889008, CMS profile ID 72414. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598889008?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ALIREZA FARABI, NPI 1598889008, CMS profile ID 72414, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1598889008?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $51,162.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $21.9406/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747966753 CMS
Gilead Sciences, Inc. $730.0006/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743815737 CMS
Janssen Biotech, Inc. $13.9706/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718962957 CMS
ViiV Healthcare Company $900.0005/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733149761 CMS
Gilead Sciences, Inc. $200.0004/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743818923 CMS
Merck Sharp & Dohme Corporation $2,310.0004/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747734241 CMS
ViiV Healthcare Company $3,680.0004/18/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733147707 CMS
Merck Sharp & Dohme Corporation $25.0004/01/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747734243 CMS
ViiV Healthcare Company $900.0003/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733134415 CMS
Merck Sharp & Dohme Corporation $101.5403/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747727583 CMS
Kowa Pharmaceuticals America, Inc. $12.7803/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716722981 CMS
Merck Sharp & Dohme Corporation $2,310.0003/04/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747734245 CMS
Gilead Sciences, Inc. $22.7903/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747966751 CMS
Merck Sharp & Dohme Corporation $150.0003/02/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747734253 CMS
Gilead Sciences, Inc. $1,730.0002/28/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743818921 CMS
Kowa Pharmaceuticals America, Inc. $13.7602/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716721585 CMS
Gilead Sciences, Inc. $28.6402/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747966747 CMS
Gilead Sciences, Inc. $116.6802/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747966749 CMS
ViiV Healthcare Company $16.6802/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733157417 CMS
Astellas Pharma US Inc $19.1602/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718320605 CMS
Janssen Biotech, Inc. $13.4502/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718962951 CMS
ViiV Healthcare Company $3,600.0002/19/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733156839 CMS
Gilead Sciences, Inc. $23.5202/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747966745 CMS
Merck Sharp & Dohme Corporation $49.0802/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747731813 CMS
Merck Sharp & Dohme Corporation $664.4902/06/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747734247 CMS
Merck Sharp & Dohme Corporation $619.5602/06/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747734249 CMS
Merck Sharp & Dohme Corporation $186.0402/06/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747734251 CMS
ViiV Healthcare Company $16.9601/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733132723 CMS
Gilead Sciences, Inc. $12.6801/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747966743 CMS
ViiV Healthcare Company $17.4001/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733138747 CMS
ViiV Healthcare Company $41.2501/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733138619 CMS
AbbVie Inc. $24.7501/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721779431 CMS
Napo Pharmaceuticals Inc $13.2501/16/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753012861 CMS
Astellas Pharma US Inc $19.1601/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718320603 CMS
Merck Sharp & Dohme Corporation $8.3801/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747697781 CMS
ViiV Healthcare Company $3,600.0001/08/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733150567 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $90,301.38 191
PY2020 $51,162.91 86
PY2021 $54,053.21 122
PY2022 $78,789.22 144
PY2023 $104,926.10 209
PY2024 $103,040.58 204
PY2025 $105,680.29 210

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $531,758.60 22
PY2024 Principal investigator $662,058.50 30
PY2023 Recipient $3,601.48 17
PY2023 Principal investigator $157,673.69 9
PY2022 Principal investigator $13,290.14 10
PY2021 Principal investigator $8,713.89 7
PY2020 Principal investigator $9,596.25 4
PY2019 Principal investigator $17,761.63 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ViiV Healthcare Company $4,120.74 12/17/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190317371
Principal investigator 1 Theratechnologies Inc. $232,720.00 12/02/2025 Non-covered Recipient Entity
Las Vegas Research Center, Inc.
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) No dispute reported 06/30/2026 1249666491
Principal investigator 1 ABBVIE INC. $6,305.00 11/04/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202520745
Principal investigator 1 ABBVIE INC. $13,288.17 10/09/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202513887
Principal investigator 1 ViiV Healthcare Company $8,700.00 09/24/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
PREFER-LA PATIENT REPORTED EXP AND BENEFIT OF TREATMENT W CABENUVA No dispute reported 06/30/2026 1190317369
Principal investigator 1 ABBVIE INC. $3,700.00 09/10/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE) Pibrentasvir (PIB) No dispute reported 06/30/2026 1202510388
Principal investigator 1 ABBVIE INC. $15,724.67 09/03/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202507153
Principal investigator 1 ABBVIE INC. $17,256.21 08/05/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202501452
Principal investigator 1 ViiV Healthcare Company $5,097.82 07/09/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190317365
Principal investigator 1 ViiV Healthcare Company $2,500.00 07/09/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190317373
Principal investigator 1 ABBVIE INC. $16,400.80 07/02/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202494325
Principal investigator 1 Gilead Sciences, Inc. $66,501.00 06/17/2025 Non-covered Recipient Entity
Las Vegas Research Center
A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV No dispute reported 06/30/2026 1229202589
Principal investigator 1 Gilead Sciences, Inc. $12,950.00 06/17/2025 Non-covered Recipient Entity
Las Vegas Research Center
A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV No dispute reported 06/30/2026 1229202595
Principal investigator 1 ABBVIE INC. $11,408.10 06/03/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202488203
Principal investigator 1 ABBVIE INC. $15,527.00 05/07/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202483391
Principal investigator 1 ViiV Healthcare Company $3,299.40 04/16/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190317363
Principal investigator 1 ViiV Healthcare Company $1,579.21 04/09/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190317361
Principal investigator 1 ABBVIE INC. $17,221.80 04/03/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202469188
Principal investigator 1 ViiV Healthcare Company $4,343.30 03/19/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190317103
Principal investigator 1 ABBVIE INC. $32,558.50 03/07/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202459562
Principal investigator 1 ABBVIE INC. $33,215.00 02/06/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202448269
Principal investigator 1 ViiV Healthcare Company $7,341.88 01/24/2025 Non-covered Recipient Entity
LAS VEGAS RESEARCH CENTER INC
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190317367